Cannabinoid system in neurodegeneration: New perspectives in Alzheimer's disease

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 539-559

  Campillo, N E ^a   Paez J A ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Alzheimer's disease; Cannabinoid; Cannabinoid receptors; CB2 agonist; Dementia; Endocannabinoid

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLDOPAMINE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AMYLOID; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; NABILONE; NOLADIN ETHER; PRAVADOLINE; RIMONABANT; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRODHAMINE; CANNABINOID RECEPTOR; LIGAND;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; CHRONIC DISEASE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LOW DRUG DOSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOSYNTHESIS; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL TRANSPORT; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; LIGANDS; RECEPTORS, CANNABINOID;

EID: 67649881952     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788167628     Document Type: Review

References (248)

1. Martinez-Gil, A. Ed. Medicinal Chemistry of Alzheimer's disease. Transworkd Research Network: India, 2008.
2. WHO World Health Statistics 2008. www.who.int 2008.
3. Wolf, S. A.; Ullrich, O. Endocannabinoids and the brain immune system: new neurones at the horizon? J. Neuroendocrinol., 2008, 20 (Suppl 1), 15-19.
4. Benito, C.; Nunez, E.; Pazos, M.R.; Tolon, R.M.; Romero, J. The endocannabinoid system and Alzheimer's disease. Mol. Neurobiol. 2007, 36, 75-81.
5. Di Marzo, V.; Petrosino, S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol., 2007, 18, 129-40.
6. Papa, S.M. The cannabinoid system in Parkinson's disease: multiple targets to motor effects. Exp. Neurol., 2008, 211, 334-38.
7. Sagredo, O.; Garcia-Arencibia, M.; de Lago, E.; Finetti, S.; Decio, A.; Fernandez-Ruiz, J. Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol., 2007, 36, 82-91.
8. Campbell, V.A.; Gowran, A. Alzheimer's disease; taking the edge off with cannabinoids? Br. J. Pharmacol., 2007, 152, 655-62.
9. Howlett, A.C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci., 1984, 35, 1803-10.
10. Howlett, A.C.; Fleming, R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol., 1984, 26, 532-38.
11. Howlett, A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol. Pharmacol., 1985, 27, 429-36.
12. Howlett, A.C.; Qualy, J.M.; Khachatrian, L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol., 1986, 29, 307-13.
13. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-64.
14. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
15. Gonzalez, A.; Duran, L.S.; Araya-Secchi, R.; Garate, J.A.; Pessoa-Mahana, C.D.; Lagos, C.F.; Perez-Acle, T. Computational modeling study of functional microdomains in cannabinoid receptor type 1. Bioorg. Med. Chem., 2008, 16, 4378-89.
16. Kreitzer, A.C.; Regehr, W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron, 2001, 29, 717-27.
17. Sullivan, J.M. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons. J Neurophysiol., 1999, 82, 1286-94.
18. Hoffman, A.F.; Lupica, C.R. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci., 2000, 20, 2470-79.
19. Alger, B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol., 2002, 68, 247-86.
20. Fisyunov, A.; Tsintsadze, V.; Min, R.; Burnashev, N.; Lozovaya, N. Cannabinoids modulate the P-type high-voltage-activated calcium currents in purkinje neurons. J. Neurophysiol., 2006, 96, 1267-77.
21. McPartland, J.; Di Marzo, V.; De Petrocellis, L.; Mercer, A.; Glass, M. Cannabinoid receptors are absent in insects. J. Comp. Neurol., 2001, 436, 423-29.
22. Pertwee, R.G. Cannabinoid receptors and pain. Prog. Neurobiol., 2001, 63, 569-611.
23. Szabo, B.; Nordheim, U.; Niederhoffer, N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J. Pharmacol. Exp. Ther., 2001, 297, 819-26.
24. Wagner, J.A.; Jarai, Z.; Batkai, S.; Kunos, G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur. J. Pharmacol., 2001, 423, 203-10.
25. Pertwee, R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 1997, 74, 129-80.
26. Croci, T.; Manara, L.; Aureggi, G.; Guagnini, F.; Rinaldi-Carmona, M.; Maffrand, J.P.; Le Fur, G.; Mukenge, S.; Ferla, G. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J. Pharmacol., 1998, 125, 1393-95.
27. Ashton, J.C.; Friberg, D.; Darlington, C.L.; Smith, P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci. Lett., 2006, 396, 113-16.
28. Gong, J.P.; Onaivi, E.S.; Ishiguro, H.; Liu, Q.R.; Tagliaferro, P.A.; Brusco, A.; Uhl, G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res., 2006, 1071, 10-23.
29. Skaper, S.D.; Buriani, A.; Dal Toso, R.; Petrelli, L.; Romanello, S.; Facci, L.; Leon, A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed post-glutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA, 1996, 93, 3984-89.
30. Svizenska, I.; Dubovy, P.; Sulcova, A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review. Pharmacol. Biochem. Behav., 2008, 90, 501-11.
31. Herkenham, M.; Lynn, A.B.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA, 1990, 87, 1932-36.
32. Herkenham, M.; Groen, B.G.; Lynn, A.B.; De Costa, B.R.; Richfield, E.K. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res., 1991, 552, 301-10.
33. Sanudo-Pena, M.C.; Patrick, S.L.; Khen, S.; Patrick, R.L.; Tsou, K.; Walker, J.M. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett., 1998, 248, 171-74.
34. Fernandez-Ruiz, J.; Romero, J.; Velasco, G.; Tolon, R.M.; Ramos, J.A.; Guzman, M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci., 2007, 28, 39-45.
35. Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Perchuk, A.; Meozzi, P.A.; Myers, L.; Mora, Z.; Tagliaferro, P.; Gardner, E.; Brusco, A.; Akinshola, B.E.; Liu, Q.R.; Hope, B.; Iwasaki, S.; Arinami, T.; Teasenfitz, L.; Uhl, G.R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N Y Acad. Sci., 2006, 1074, 514-36.
36. Nunez, E.; Benito, C.; Pazos, M.R.; Barbachano, A.; Fajardo, O.; Gonzalez, S.; Tolon, R.M.; Romero, J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse, 2004, 53, 208-13.
37. Stella, N. Cannabinoid signaling in glial cells. Glia, 2004, 48, 267-77.
38. Maresz, K.; Carrier, E. J.; Ponomarev, E. D.; Hillard, C. J.; Dittel, B. N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem., 2005, 95, 437-45.
39. Palazuelos, J.; Aguado, T.; Egia, A.; Mechoulam, R.; Guzman, M.; Galve-Roperh, I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J., 2006, 20, 2405-07.
40. Molina-Holgado, E.; Vela, J.M.; Arevalo-Martin, A.; Almazan, G.; Molina-Holgado, F.; Borrell, J.; Guaza, C. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci., 2002, 22, 9742-53.
41. Ross, R.A.; Coutts, A.A.; McFarlane, S.M.; Anavi-Goffer, S.; Irving, A.J.; Pertwee, R.G.; MacEwan, D.J.; Scott, R.H. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology, 2001, 40, 221-32.
42. Stander, S.; Schmelz, M.; Metze, D.; Luger, T.; Rukwied, R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J. Dermatol. Sci., 2005, 38, 177-88.
43. Van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J.S.; Marnett, L.J.; Di Marzo, V.; Pittman, Q.J.; Patel, K.D.; Sharkey, K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 2005, 310, 329-32.
44. Wotherspoon, G.; Fox, A.; McIntyre, P.; Colley, S.; Bevan, S.; Winter, J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience, 2005, 135, 235-45.
45. Beltramo, M.; Bernardini, N.; Bertorelli, R.; Campanella, M.; Nicolussi, E.; Fredduzzi, S.; Reggiani, A. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci., 2006, 23, 1530-38.
46. Bouaboula, M.; Desnoyer, N.; Carayon, P.; Combes, T.; Casellas, P. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol. Pharmacol., 1999, 55, 473-80.
47. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol., 1998, 54, 1064-72.
48. Mato, S.; Pazos, A.; Valdizan, E.M. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur. J. Pharmacol., 2002, 443, 43-46.
49. Meschler, J.P.; Kraichely, D.M.; Wilken, G.H.; Howlett, A.C. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem. Pharmacol., 2000, 60, 1315-23.
50. Kearn, C.S.; Greenberg, M.J.; DiCamelli, R.; Kurzawa, K.; Hillard, C.J. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem., 1999, 72, 2379-87.
51. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289, 739-45.
52. Okada, T.; Fujiyoshi, Y.; Silow, M.; Navarro, J.; Landau, E. M.; Shichida, Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl. Acad. Sci. U S A, 2002, 99, 5982-87.
53. Li, J.; Edwards, P.C.; Burghammer, M.; Villa, C.; Schertler, G.F. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol., 2004, 343, 1409-38.
54. Okada, T.; Sugihara, M.; Bondar, A.N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J. Mol. Biol., 2004, 342, 571-83.
55. Colquhoun, D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol., 1998, 125, 924-47.
56. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev., 2000, 21, 90-113.
57. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258, 1946-49.
58. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R.; Pertwee, R.G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50, 83-90.
59. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 1995, 215, 89-97.
60. Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.E.; Kustanovich, I.; Mechoulam, R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U S A, 2001, 98, 3662-65.
61. Porter, A. C.; Sauer, J. M.; Knierman, M. D.; Becker, G. W.; Berna, M. J.; Bao, J.; Nomikos, G. G.; Carter, P.; Bymaster, F. P.; Leese, A. B.; Felder, C. C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 2002, 301, 1020-24.
62. Huang, S. M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T. J.; Krey, J. F.; Chu, C. J.; Miller, J. D.; Davies, S. N.; Geppetti, P.; Walker, J. M.; Di Marzo, V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U S A., 2002, 99, 8400-05.
63. Hanus, L.; Gopher, A.; Almog, S.; Mechoulam, R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem., 1993, 36, 3032-34.
64. Glass, M.; Northup, J. K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol., 1999, 56, 1362-69.
65. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A. L.; Mitchell, R. L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 1995, 48, 443-50.
66. Farquhar-Smith, W. P.; Egertova, M.; Bradbury, E. J.; McMahon, S. B.; Rice, A. S. C.; Elphick, M. R. Cannabinoid CB1 Receptor Expression in Rat Spinal Cord. Mol. Cell. Neurosci. 2000, 15, 510-21.
67. Sugiura, T.; Waku, K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem. Phys. Lipids, 2000, 108, 89-106.
68. Childers, S. R.; Breivogel, C. S. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend, 1998, 51, 173-87.
69. Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D. E.; Kustanovich, I.; Mechoulam, R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U S A., 2001, 98, 3662-65.
70. Fezza, F.; Bisogno, T.; Minassi, A.; Appendino, G.; Mechoulam, R.; Di Marzo, V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett., 2002, 513, 294-98.
71. Bisogno, T.; Melck, D.; Bobrov, M.; Gretskaya, N. M.; Bezuglov, V. V.; De Petrocellis, L.; Di Marzo, V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J., 2000, 351 Pt 3, 817-24.
72. Alexander, S. P.; Kendall, D. A. The complications of promiscuity: endocannabinoid action and metabolism. Br. J. Pharmacol., 2007, 152, 602-23.
73. Saario, S. M.; Laitinen, J. T. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin. Pharmacol. Toxicol., 2007, 101, 287-93.
74. Gomez-Ruiz, M.; Hernandez, M.; de Miguel, R.; Ramos, J. A. An overview on the biochemistry of the cannabinoid system. Mol. Neurobiol., 2007, 36, 3-14.
75. Di Marzo, V. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol., 2008, 160, 1-24.
76. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J. C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372, 686-91.
77. Okamoto, Y.; Morishita, J.; Tsuboi, K.; Tonai, T.; Ueda, N. Molecular characterization of a phospholipase d generating anandamide and its congeners. J. Biol. Chem., 2004, 279, 5298-5305.
78. Astarita, G.; Ahmed, F.; Piomelli, D. Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. J. Lipid Res., 2008, 49, 48-57.
79. Ben-Shabat, S.; Fride, E.; Sheskin, T.; Tamiri, T.; Rhee, M. H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzo, V.; Mechoulam, R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol., 1998, 353, 23-31.
80. Bisogno, T.; Melck, D.; De Petrocellis, L.; Di Marzo, V. Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem., 1999, 72, 2113-19.
81. Carrier, E. J.; Kearn, C. S.; Barkmeier, A. J.; Breese, N. M.; Yang, W.; Nithipatikom, K.; Pfister, S. L.; Campbell, W. B.; Hillard, C. J. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol., 2004, 65, 999-1007.
82. Hillard, C. J.; Edgemond, W. S.; Jarrahian, A.; Campbell, W. B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem., 1997, 69, 631-38.
83. Beltramo, M.; Stella, N.; Calignano, A.; Lin, S. Y.; Makriyannis, A.; Piomelli, D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 1997, 277, 1094-97.
84. Piomelli, D.; Beltramo, M.; Glasnapp, S.; Lin, S. Y.; Goutopoulos, A.; Xie, X.-Q.; Makriyannis, A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA, 1999, 96, 5802-07.
85. Vandevoorde, S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr. Top. Med. Chem., 2008, 8, 247-67.
86. Bari, M.; Battista, N.; Fezza, F.; Gasperi, V.; Maccarrone, M. New insights into endocannabinoid degradation and its therapeutic potential. Mini. Rev. Med. Chem., 2006, 6, 257-68.
87. Maccarrone, M. Fatty acid amide hydrolase: a potential target for next generation therapeutics. Curr. Pharm. Des., 2006, 12, 759-72.
88. Nunez, E.; Benito, C.; Tolon, R. M.; Hillard, C. J.; Griffin, W. S.; Romero, J. Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience, 2008, 151, 104-10.
89. Di Marzo, V.; Maccarrone, M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol. Sci., 2008, 29, 229-33.
90. Piomelli, D.; Tarzia, G.; Duranti, A.; Tontini, A.; Mor, M.; Compton, T. R.; Dasse, O.; Monaghan, E. P.; Parrott, J. A.; Putman, D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev., 2006, 12, 21-38.
91. Cupini, L. M.; Costa, C.; Sarchielli, P.; Bari, M.; Battista, N.; Eusebi, P.; Calabresi, P.; Maccarrone, M. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol. Dis., 2008, 30, 186-89.
92. Lunn, C. A.; Reich, E. P.; Bober, L. Targeting the CB2 receptor for immune modulation. Expert Opin. Ther. Targets, 2006, 10, 653-63.
93. Massi, P.; Vaccani, A.; Parolaro, D. Cannabinoids, immune system and cytokine network. Curr. Pharm. Des., 2006, 12, 3135-46.
94. Woods, S. C. Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am. J. Med., 2007, 120, S19-25.
95. Hiley, C. R.; Hoi, P. M. Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? Cardiovasc. Drug Rev., 2007, 25, 46-60.
96. Ashton, J. C.; Smith, P. F. Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Curr. Vasc. Pharmacol., 2007, 5, 175-85.
97. Maccarrone, M.; Wenger, T. Effects of cannabinoids on hypothalamic and reproductive function. Handb. Exp. Pharmacol., 2005, 555-71.
98. Battista, N.; Rapino, C.; Di Tommaso, M.; Bari, M.; Pasquariello, N.; Maccarrone, M. Regulation of male fertility by the endocannabinoid system. Mol. Cell Endocrinol., 2008, 286, S17-23.
99. Maccarrone, M. CB2 receptors in reproduction. Br. J. Pharmacol., 2008, 153, 189-98.
100. Matias, I.; Di Marzo, V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab., 2007, 18, 27-37.
101. El Manira, A.; Kyriakatos, A.; Nanou, E.; Mahmood, R. Endocannabinoid signaling in the spinal locomotor circuitry. Brain Res. Rev., 2008, 57, 29-36.
102. Benarroch, E. Endocannabinoids in basal ganglia circuits: implications for Parkinson disease. Neurology, 2007, 69, 306-09.
103. Lastres-Becker, I.; Fernandez-Ruiz, J. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Curr. Med. Chem., 2006, 13, 3705-18.
104. de Lago, E.; Fernandez-Ruiz, J. Cannabinoids and neuroprotection in motor-related disorders. CNS Neurol. Disord. Drug Targets, 2007, 6, 377-87.
105. Maccarrone, M.; Battista, N.; Centonze, D. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog. Neurobiol., 2007, 81, 349-79.
106. Micale, V.; Mazzola, C.; Drago, F. Endocannabinoids and neurodegenerative diseases. Pharmacol. Res., 2007, 56, 382-92.
107. McCarberg, B. H. Cannabinoids:their role in pain and palliation. J. Pain Palliat. Care Pharmacother., 2007, 21, 19-28.
108. Guindon, J.; Hohmann, A. G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol., 2008, 153, 319-34.
109. Ashton, J. C.; Milligan, E. D. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr. Opin. Investig. Drugs, 2008, 9, 65-75.
110. Jhaveri, M. D.; Richardson, D.; Chapman, V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol., 2007, 152, 624-32.
111. Solinas, M.; Goldberg, S. R.; Piomelli, D. The endocannabinoid system in brain reward processes. Br. J. Pharmacol., 2008, 154, 369-83.
112. Wotjak, C. T. Role of endogenous cannabinoids in cognition and emotionality. Mini Rev. Med. Chem., 2005, 5, 659-70.
113. Baker, D.; Pryce, G. The endocannabinoid system and multiple sclerosis. Curr. Pharm. Des., 2008, 14, 2326-36.
114. Docagne, F.; Mestre, L.; Loria, F.; Hernangomez, M.; Correa, F.; Guaza, C. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin. Ther. Targets, 2008, 12, 185-95.
115. Papathanasopoulos, P.; Messinis, L.; Lyros, E.; Kastellakis, A.; Panagis, G. Multiple sclerosis, cannabinoids, and cognition. J. Neuropsychiatry Clin. Neurosci., 2008, 20, 36-51.
116. Elsohly, M. A.; Slade, D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci., 2005, 78, 539-48.
117. Padgett, L. W. Recent developments in cannabinoid ligands. Life Sci., 2005, 77, 1767-98.
118. Huffman, J. W. CB2 receptor ligands. Mini Rev. Med. Chem., 2005, 5, 641-49.
119. Marriott, K. S.; Huffman, J. W.; Wiley, J. L.; Martin, B. R. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor. Bioorg. Med. Chem., 2006, 14, 2386-97.
120. Manera, C.; Tuccinardi, T.; Martinelli, A. Indoles and related compounds as cannabinoid ligands. Mini Rev. Med. Chem., 2008, 8, 370-87.
121. Marriott, K. S.; Huffman, J. W. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr. Top. Med. Chem., 2008, 8, 187-204.
122. Woelkart, K.; Salo-Ahen, O. M.; Bauer, R. CB receptor ligands from plants. Curr. Top. Med. Chem., 2008, 8, 173-86.
123. Poso, A.; Huffman, J. W. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. Br. J. Pharmacol., 2008, 153, 335-46.
124. Shire, D.; Calandra, B.; Bouaboula, M.; Barth, F.; Rinaldi-Carmona, M.; Casellas, P.; Ferrara, P. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci., 1999, 65, 627-35.
125. Barth, F.; Rinaldi-Carmona, M. The development of cannabinoid antagonists. Curr. Med. Chem., 1999, 6, 745-55.
126. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D.; Ferrar, P.; Soubrie, P.; Breliere, J.C.; Fur, G.L. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 1994, 350, 240-44.
127. Bifulco, M.; Grimaldi, C.; Gazzerro, P.; Pisanti, S.; Santoro, A. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol. Pharmacol., 2007, 71, 1445-56.
128. Pertwee, R. G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci., 2005, 76, 1307-24.
129. Jagerovic, N.; Fernandez-Fernandez, C.; Goya, P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr. Top. Med. Chem., 2008, 8, 205-30.
130. Salamone, J. D.; McLaughlin, P. J.; Sink, K.; Makriyannis, A.; Parker, L. A. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol. Behav., 2007, 91, 383-88.
131. Lunn, C. A.; Reich, E. P.; Fine, J. S.; Lavey, B.; Kozlowski, J. A.; Hipkin, R. W.; Lundell, D. J.; Bober, L. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br. J. Pharmacol., 2008, 153, 226-39.
132. Muccioli, G. G. Blocking the cannabinoid receptors: drug candidates and therapeutic promises. Chem. Biodivers., 2007, 4, 1805-27.
133. Raitio, K. H.; Savinainen, J. R.; Nevalainen, T.; Jarvinen, T.; Vepsalainen, J. Synthesis and in vitro evaluation of novel 2-oxo-1,2-dihydroquinoline CB2 receptor inverse agonists. Chem. Biol. Drug Des., 2006, 68, 334-40.
134. Lange, J. H.; Kruse, C. G. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov. Today, 2005, 10, 693-702.
135. Savinainen, J. R.; Kokkola, T.; Salo, O. M.; Poso, A.; Jarvinen, T.; Laitinen, J. T. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br. J. Pharmacol., 2005, 145, 636-45.
136. Silvestri, R.; Cascio, M. G.; La Regina, G.; Piscitelli, F.; Lavecchia, A.; Brizzi, A.; Pasquini, S.; Botta, M.; Novellino, E.; Di Marzo, V.; Corelli, F. Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. J. Med. Chem., 2008, 51, 1560-76.
137. Pertwee, R.; Griffin, G.; Fernando, S.; Li, X.; Hill, A.; Makriyannis, A. AM630, a competitive cannabinoid receptor antagonist. Life Sci., 1995, 56, 1949-55.
138. Devane, W. A.; Dysarz, F. A., 3rd; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 1988, 34, 605-13.
139. Gaoni, Y.; Mechoulam, R. The Isolation and Structure of A'-Tetrahydrocannabinol and Other Neutral Cannabinoids from Hashish. J. Am. Chem. Soc., 1964, 86, 1646-47.
140. Iwamura, H.; Suzuki, H.; Ueda, Y.; Kaya, T.; Inaba, T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther., 2001, 296, 420-25.
141. Thomas, A.; Stevenson, L. A.; Wease, K. N.; Price, M. R.; Baillie, G.; Ross, R. A.; Pertwee, R. G. Evidence that the plant cannabinoid Delta(9)-tetrahydrocannabivarin is a cannabinoid CB(1) and CB(2) receptor antagonist. Br. J. Pharmacol., 2005, 146, 917-26.
142. Costa, B. On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem. Biodivers., 2007, 4, 1664-77.
143. Pertwee, R. G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol., 2008, 153, 199-215.
144. Mechoulam, R.; Peters, M.; Murillo-Rodriguez, E.; Hanus, L. O. Cannabidiol - recent advances. Chem. Biodivers., 2007, 4, 1678-92.
145. Thomas, A.; Baillie, G. L.; Phillips, A. M.; Razdan, R. K.; Ross, R. A.; Pertwee, R. G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol., 2007, 150, 613-23.
146. Herkenham, M.; Lynn, A. B.; Johnson, M. R.; Melvin, L. S.; de Costa, B. R.; Rice, K. C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci., 1991, 11, 563-83.
147. Gareau, Y. D., Claude; Gallant, Michel; Rochette, Chantal; Sawyer, Nicole; Slipetz, Deborah M.; Tremblay, Nathalie; Weech, Philip K.; Metters, Kathleen M.; Labelle, Marc Structure activity relationships of tetrahydrocanabinol analogs on human cannabinoid receptors. Bioorg. Med. Chem. Lett., 1996, 6, 189-94.
148. Little, P. J.; Compton, D. R.; Johnson, M. R.; Melvin, L. S.; Martin, B. R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther., 1988, 247, 1046-51.
149. Little, P. J.; Compton, D. R.; Mechoulam, R.; Martin, B. R. Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol. Biochem. Behav., 1989, 32, 661-66.
150. Jarbe, T. U.; Hiltunen, A. J.; Mechoulam, R. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. J. Pharmacol. Exp. Ther., 1989, 250, 1000-05.
151. Govaerts, S. J.; Hermans, E.; Lambert, D. M. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur. J. Pharm. Sci., 2004, 23, 233-43.
152. Huffman, J. W.; Yu, S.; Showalter, V.; Abood, M. E.; Wiley, J. L.; Compton, D. R.; Martin, B. R.; Bramblett, R. D.; Reggio, P. H. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem., 1996, 39, 3875-77.
153. Huffman, J. W.; Zengin, G.; Wu, M. J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L.; Bushell, S.; Tartal, C.; Hurst, D. P.; Reggio, P. H.; Selley, D. E.; Cassidy, M. P.; Wiley, J. L.; Martin, B. R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg. Med. Chem., 2005, 13, 89-112.
154. Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fride, E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U S A., 1999, 96, 14228-33.
155. Huffman, J. W.; Bushell, S. M.; Joshi, S. N.; Wiley, J. L.; Martin, B. R. Enantioselective synthesis of 1-methoxy- and 1-deoxy-2′-methyl-delta8-tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorg. Med. Chem., 2006, 14, 247-62.
156. Wiley, J. L.; Beletskaya, I. D.; Ng, E. W.; Dai, Z.; Crocker, P. J.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J. Pharmacol. Exp. Ther., 2002, 301, 679-89.
157. Khanolkar, A. D.; Lu, D.; Ibrahim, M.; Duclos, R. I., Jr.; Thakur, G. A.; Malan, T. P., Jr.; Porreca, F.; Veerappan, V.; Tian, X.; George, C.; Parrish, D. A.; Papahatjis, D. P.; Makriyannis, A. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J. Med. Chem., 2007, 50, 6493-500.
158. Worm, K.; Zhou, Q. J.; Stabley, G. J.; DeHaven, R. N.; Dolle, R. E. Biaryl cannabinoid mimetics - synthesis and structure-activity relationship. Bioorg. Med. Chem. Lett., 2007, 17, 3652-56.
159. Bell, M. R.; D'Ambra, T. E.; Kumar, V.; Eissenstat, M. A.; Herrmann, J. L., Jr.; Wetzel, J. R.; Rosi, D.; Philion, R. E.; Daum, S. J.; Hlasta, D. J.; et al. Antinociceptive (aminoalkyl)indoles. J. Med. Chem., 1991, 34, 1099-110.
160. D'Ambra, T. E.; Estep, K. G.; Bell, M. R.; Eissenstat, M. A.; Josef, K. A.; Ward, S. J.; Haycock, D. A.; Baizman, E. R.; Casiano, F. M.; Beglin, N. C.; et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl) indole agonists of the cannabinoid receptor. J. Med. Chem., 1992, 35, 124-35.
161. Huffman, J. W.; Padgett, L. W. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem., 2005, 12, 1395-411.
162. Showalter, V. M.; Compton, D. R.; Martin, B. R.; Abood, M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 1996, 278, 989-99.
163. Gallant, M. D., Claude; Gareau, Yves; Guay, Daniel; Leblanc, Yves; Prasit, Petipibbon; Rochette, Chantal; Sawyer, Nicole; Slipetz, Deborah M.; et al. New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg. Med. Chem. Lett., 1996, 6, 2263-68.
164. Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacol., 2005, 48, 658-72.
165. Bingham, B.; Jones, P. G.; Uveges, A. J.; Kotnis, S.; Lu, P.; Smith, V. A.; Sun, S. C.; Resnick, L.; Chlenov, M.; He, Y.; Strassle, B. W.; Cummons, T. A.; Piesla, M. J.; Harrison, J. E.; Whiteside, G. T.; Kennedy, J. D. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br. J. Pharmacol., 2007, 151, 1061-70.
166. Malan, T. P., Jr.; Ibrahim, M. M.; Deng, H.; Liu, Q.; Mata, H. P.; Vanderah, T.; Porreca, F.; Makriyannis, A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain, 2001, 93, 239-45.
167. Ibrahim, M. M.; Deng, H.; Zvonok, A.; Cockayne, D. A.; Kwan, J.; Mata,
168. Hynes, J., Jr.; Leftheris, K.; Wu, H.; Pandit, C.; Chen, P.; Norris, D. J.; Chen, B. C.; Zhao, R.; Kiener, P. A.; Chen, X.; Turk, L. A.; Patil-Koota, V.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W. C-3 Amido-indole cannabinoid receptor modulators. Bioorg. Med. Chem. Lett., 2002, 12, 2399-402.
169. Yao, B. B.; Hsieh, G. C.; Frost, J. M.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Zhu, C. Z.; Pai, M.; Chandran, P.; Salyers, A. K.; Wensink, E. J.; Honore, P.; Sullivan, J. P.; Dart, M. J.; Meyer, M. D. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br. J. Pharmacol., 2008, 153, 390-401.
170. Frost, J. M.; Dart, M. J.; Tietje, K. R.; Garrison, T. R.; Grayson, G. K.; Daza, A. V.; El-Kouhen, O. F.; Miller, L. N.; Li, L.; Yao, B. B.; Hsieh, G. C.; Pai, M.; Zhu, C. Z.; Chandran, P.; Meyer, M. D. Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity. J. Med. Chem., 2008, 51, 1904-12.
171. Brizzi, A.; Brizzi, V.; Cascio, M. G.; Bisogno, T.; Sirianni, R.; Di Marzo, V. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. J. Med. Chem., 2005, 48, 7343-50.
172. Huffman, J. W.; Padgett, L. W.; Isherwood, M. L.; Wiley, J. L.; Martin, B. R. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg. Med. Chem. Lett., 2006, 16, 5432-35.
173. Wrobleski, S. T.; Chen, P.; Hynes, J., Jr.; Lin, S.; Norris, D. J.; Pandit, C. R.; Spergel, S.; Wu, H.; Tokarski, J. S.; Chen, X.; Gillooly, K. M.; Kiener, P. A.; McIntyre, K. W.; Patil-Koota, V.; Shuster, D. J.; Turk, L. A.; Yang, G.; Leftheris, K. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J. Med. Chem., 2003, 46, 2110-16.
174. Ferrarini, P. L.; Calderone, V.; Cavallini, T.; Manera, C.; Saccomanni, G.; Pani, L.; Ruiu, S.; Gessa, G. L. Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. Bioorg. Med. Chem., 2004, 12, 1921-33.
175. Mussinu, J.-M.; Ruiu, S.; Mule, A. C.; Pau, A.; Carai, M. A. M.; Loriga, G.; Murineddu, G.; Pinna, G. A. Tricyclic Pyrazoles. Part 1: Synthesis and Biological Evaluation of Novel 1,4-Dihydroindeno[1,2-c]pyrazol-based Ligands for CB1and CB2 Cannabinoid Receptors. Bioorg. Med. Chem., 2003, 11, 251-63.
176. Manera, C.; Benetti, V.; Castelli, M. P.; Cavallini, T.; Lazzarotti, S.; Pibiri, F.; Saccomanni, G.; Tuccinardi, T.; Vannacci, A.; Martinelli, A.; Ferrarini, P. L. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J. Med. Chem., 2006, 49, 5947-57.
177. Stern, E.; Muccioli, G. G.; Millet, R.; Goossens, J. F.; Farce, A.; Chavatte, P.; Poupaert, J. H.; Lambert, D. M.; Depreux, P.; Henichart, J. P. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J. Med. Chem., 2006, 49, 70-79.
178. Gonsiorek, W.; Lunn, C. A.; Fan, X.; Deno, G.; Kozlowski, J.; Hipkin, R. W. Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. Br. J. Pharmacol., 2007, 151, 1262-71.
179. Kai, H.; Morioka, Y.; Murashi, T.; Morita, K.; Shinonome, S.; Nakazato, H.; Kawamoto, K.; Hanasaki, K.; Takahashi, F.; Mihara, S.; Arai, T.; Abe, K.; Okabe, H.; Baba, T.; Yoshikawa, T.; Takenaka, H. 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: discovery of CB2 receptor selective compounds. Bioorg. Med. Chem. Lett., 2007, 17, 4030-34.
180. Kai, H.; Morioka, Y.; Tomida, M.; Takahashi, T.; Hattori, M.; Hanasaki, K.; Koike, K.; Chiba, H.; Shinohara, S.; Kanemasa, T.; Iwamoto, Y.; Takahashi, K.; Yamaguchi, Y.; Baba, T.; Yoshikawa, T.; Takenaka, H. 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds. Bioorg. Med. Chem. Lett., 2007, 17, 3925-29.
181. Eatherton, A.J.G.; Paul, G.M.; Howard, G.R.; Leonard, M.W.; Rawlings, N.A.; Anthony, D.; Peter, S.B.; Richard, W.A. Preparation of aminopyrimidinecarboxamides and their use as CB2-type cannabinoid receptor modulators. In 129 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). Ge: PCT Int. Appl. WO 2004018433 A1 4 Mar 2004.
182. Giblin, G. M.; O'Shaughnessy, C. T.; Naylor, A.; Mitchell, W. L.; Eatherton, A. J.; Slingsby, B. P.; Rawlings, D. A.; Goldsmith, P.; Brown, A. J.; Haslam, C. P.; Clayton, N. M.; Wilson, A. W.; Chessell, I. P.; Wittington, A. R.; Green, R. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl) methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J. Med. Chem., 2007, 50, 2597-600.
183. Ermann, M.; Riether, D.; Walker, E. R.; Mushi, I. F.; Jenkins, J. E.; Noya-Marino, B.; Brewer, M. L.; Taylor, M. G.; Amouzegh, P.; East, S. P.; Dymock, B. W.; Gemkow, M. J.; Kahrs, A. F.; Ebneth, A.; Lobbe, S.; O'Shea, K.; Shih, D. T.; Thomson, D. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. Bioorg. Med. Chem. Lett., 2008, 18, 1725-29.
184. Verbist, B. M.; De Cleyn, M. A.; Surkyn, M.; Fraiponts, E.; Aerssens, J.; Nijsen, M. J.; Gijsen, H. J. 5-Sulfonyl-benzimidazoles as selective CB2 agonists. Bioorg. Med. Chem. Lett., 2008, 18, 2574-79.
185. Bramblett, R. D.; Panu, A. M.; Ballesteros, J. A.; Reggio, P. H. Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. Life Sci., 1995, 56, 1971-82.
186. Song, Z. H.; Slowey, C. A.; Hurst, D. P.; Reggio, P. H. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol. Pharmacol., 1999, 56, 834-40.
187. McAllister, S. D.; Tao, Q.; Barnett-Norris, J.; Buehner, K.; Hurst, D. P.; Guarnieri, F.; Reggio, P. H.; Nowell Harmon, K. W.; Cabral, G. A.; Abood, M. E. A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem. Pharmacol., 2002, 63, 2121-36.
188. Mahmoudian, M. The cannabinoid receptor: computer-aided molecular modeling and docking of ligand. J. Mol. Graph Model, 1997, 15, 149-153, 179.
189. Henderson, R.; Baldwin, J. M.; Ceska, T. A.; Zemlin, F.; Beckmann, E.; Downing, K. H. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J. Mol. Biol., 1990, 213, 899-929.
190. Salo, O. M.; Raitio, K. H.; Savinainen, J. R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J. T.; Jarvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J. Med. Chem., 2005, 48, 7166-71.
191. Xie, X. Q.; Chen, J. Z.; Billings, E. M. 3D structural model of the Gprotein-coupled cannabinoid CB2 receptor. Proteins, 2003, 53, 307-19.
192. Montero, C.; Campillo, N. E.; Goya, P.; Paez, J. A. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. Eur. J. Med. Chem., 2005, 40, 75-83.
193. Yates, A. S.; Doughty, S. W.; Kendall, D. A.; Kellam, B. Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor. Bioorg. Med. Chem. Lett., 2005, 15, 3758-62.
194. Zhang, R.; Hurst, D. P.; Barnett-Norris, J.; Reggio, P. H.; Song, Z. H. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template. Mol. Pharmacol., 2005, 68, 69-83.
195. Raduner, S.; Majewska, A.; Chen, J. Z.; Xie, X. Q.; Hamon, J.; Faller, B.; Altmann, K. H.; Gertsch, J. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J. Biol. Chem., 2006, 281, 14192-206.
196. Tuccinardi, T.; Ferrarini, P. L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. J. Med. Chem., 2006, 49, 984-94.
197. Shim, J. Y.; Welsh, W. J.; Howlett, A. C. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers, 2003, 71, 169-89.
198. Salo, O. M.; Lahtela-Kakkonen, M.; Gynther, J.; Jarvinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem., 2004, 47, 3048-57.
199. McAllister, S. D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Abood, M. E. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem., 2003, 46, 5139-52.
200. Hurst, D. P.; Lynch, D. L.; Barnett-Norris, J.; Hyatt, S. M.; Seltzman, H. H.; Zhong, M.; Song, Z. H.; Nie, J.; Lewis, D.; Reggio, P. H. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-p yrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol., 2002, 62, 1274-87.
201. Raitio, K. H.; Salo, O. M.; Nevalainen, T.; Poso, A.; Jarvinen, T. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. Curr. Med. Chem., 2005, 12, 1217-37.
202. Dainese, E.; Oddi, S.; Maccarrone, M. Lipid-mediated dimerization of beta(2)-adrenergic receptor reveals important clues for cannabinoid receptors. Cell Mol. Life Sci., 2008, 65, 2277-79.
203. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 2007, 318, 1258-65.
204. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science, 2007, 318, 1266-73.
205. Hanson, M. A.; Cherezov, V.; Griffith, M. T.; Roth, C. B.; Jaakola, V. P.; Chien, E. Y.; Velasquez, J.; Kuhn, P.; Stevens, R. C. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure, 2008, 16, 897-905.
206. Sansom, M. S.; Weinstein, H. Hinges, swivels and switches: the role of prolines in signalling via transmembrane alpha-helices. Trends Pharmacol. Sci., 2000, 21, 445-51.
207. Singh, R.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Guarnieri, F. Activation of the cannabinoid CB1 receptor may involve a W6 48/F3 36 rotamer toggle switch. J. Pept. Res., 2002, 60, 357-70.
208. Javitch, J. A.; Fu, D.; Liapakis, G.; Chen, J. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J. Biol. Chem., 1997, 272, 18546-49.
209. Song, Z. H.; Bonner, T. I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol., 1996, 49, 891-96.
210. Reggio, P. H. Cannabinoid receptors and their ligands: ligandligand and ligand-receptor modeling approaches. Handb. Exp. Pharmacol., 2005, 247-81.
211. Ortega-Gutierrez, S.; Lopez-Rodriguez, M. L. CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches. Mini. Rev. Med. Chem., 2005, 5, 651-58.
212. Mandavilli, A. The amyloid code. Nat. Med., 2006, 12, 747-51.
213. Klafki, H. W.; Staufenbiel, M.; Kornhuber, J.; Wiltfang, J. Therapeutic approaches to Alzheimer's disease. Brain, 2006, 129, 2840-55.
214. Claassen, J. A.; Jansen, R. W. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J. Gerontol. A. Biol. Sci. Med. Sci., 2006, 61, 267-71.
215. Coulthard, E.; Singh-Curry, V.; Husain, M. Treatment of attention deficits in neurological disorders. Curr. Opin. Neurol., 2006, 19, 613-18.
216. Villarroya, M.; Garcia, A. G.; Marco-Contelles, J.; Lopez, M. G. An update on the pharmacology of galantamine. Expert Opin. Investig. Drugs, 2007, 16, 1987-98.
217. Kamal, M. A.; Qu, X.; Yu, Q. S.; Tweedie, D.; Holloway, H. W.; Li, Y.; Tan, Y.; Greig, N. H. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J. Neural. Transm., 2008, 115, 889-98.
218. Lane, R. M.; Potkin, S. G.; Enz, A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol., 2006, 9, 101-24.
219. Annicchiarico, R.; Federici, A.; Pettenati, C.; Caltagirone, C. Rivastigmine in Alzheimer's disease: Cognitive function and quality of life. Ther. Clin. Risk. Manag., 2007, 3, 1113-23.
220. Bullock, R.; Lane, R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr. Alzheimer Res., 2007, 4, 277-93.
221. Chen, H. S.; Lipton, S. A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem., 2006, 97, 1611-26.
222. Goto, Y.; Niidome, T.; Akaike, A.; Kihara, T.; Sugimoto, H. Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. Biochem. Biophys. Res. Commun., 2006, 351, 259-65.
223. Benito, C.; Tolon, R. M.; Pazos, M. R.; Nunez, E.; Castillo, A. I.; Romero, J. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol., 2008, 153, 277-85.
224. Bisogno, T.; Di Marzo, V. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr. Pharm. Des., 2008, 14, 2299-3305.
225. Fernandez-Ruiz, J.; Pazos, M. R.; Garcia-Arencibia, M.; Sagredo, O.; Ramos, J. A. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol. Cell. Endocrinol., 2008, 286, S91-96.
226. Milton, N. G. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett., 2002, 332, 127-30.
227. Ramirez, B. G.; Blazquez, C.; Gomez del Pulgar, T.; Guzman, M.; de Ceballos, M. L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci., 2005, 25, 1904-13.
228. Ehrhart, J.; Obregon, D.; Mori, T.; Hou, H.; Sun, N.; Bai, Y.; Klein, T.; Fernandez, F.; Tan, J.; Shytle, R. D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflamm., 2005, 2, 29.
229. Eljaschewitsch, E.; Witting, A.; Mawrin, C.; Lee, T.; Schmidt, P. M.; Wolf, S.; Hoertnagl, H.; Raine, C. S.; Schneider-Stock, R.; Nitsch, R.; Ullrich, O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron, 2006, 49, 67-79.
230. Iuvone, T.; Esposito, G.; Esposito, R.; Santamaria, R.; Di Rosa, M.; Izzo, A.A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem., 2004, 89, 134-41.
231. Esposito, G.; De Filippis, D.; Steardo, L.; Scuderi, C.; Savani, C.; Cuomo, V.; Iuvone, T. CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci. Lett., 2006, 404, 342-46.
232. Esposito, G.; De Filippis, D.; Carnuccio, R.; Izzo, A. A.; Iuvone, T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J. Mol. Med., 2006, 84, 253-58.
233. Esposito, G.; De Filippis, D.; Maiuri, M. C.; De Stefano, D.; Carnuccio, R.; Iuvone, T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in betaamyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci. Lett., 2006, 399, 91-95.
234. van der Stelt, M.; Mazzola, C.; Esposito, G.; Matias, I.; Petrosino, S.; De Filippis, D.; Micale, V.; Steardo, L.; Drago, F.; Iuvone, T.; Di Marzo, V. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol. Life Sci., 2006, 63, 1410-24.
235. Panikashvili, D.; Simeonidou, C.; Ben-Shabat, S.; Hanus, L.; Breuer, A.; Mechoulam, R.; Shohami, E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 2001, 413, 527-31.
236. Hansen, H. H.; Schmid, P. C.; Bittigau, P.; Lastres-Becker, I.; Berrendero, F.; Manzanares, J.; Ikonomidou, C.; Schmid, H. H.; Fernandez-Ruiz, J. J.; Hansen, H. S. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem., 2001, 78, 1415-27.
237. Marchalant, Y.; Rosi, S.; Wenk, G. L. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience, 2007, 144, 1516-22.
238. Volicer, L.; Stelly, M.; Morris, J.; McLaughlin, J.; Volicer, B. J. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry, 1997, 12, 913-19.
239. Walther, S.; Mahlberg, R.; Eichmann, U.; Kunz, D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl.), 2006, 185, 524-28.
240. Garcia-Arencibia, M.; Gonzalez, S.; de Lago, E.; Ramos, J. A.; Mechoulam, R.; Fernandez-Ruiz, J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res., 2007, 1134, 162-70.
241. Arevalo-Martin, A.; Vela, J. M.; Molina-Holgado, E.; Borrell, J.; Guaza, C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci., 2003, 23, 2511-16.
242. Fernandez-Lopez, D.; Martinez-Orgado, J.; Nunez, E.; Romero, J.; Lorenzo, P.; Moro, M. A.; Lizasoain, I. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr. Res., 2006, 60, 169-73.
243. Kim, K.; Moore, D. H.; Makriyannis, A.; Abood, M. E. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol., 2006, 542, 100-05.
244. Zhang, M.; Martin, B. R.; Adler, M. W.; Razdan, R. K.; Jallo, J. I.; Tuma, R. F. Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood Flow Metab., 2007, 27, 1387-96.
245. Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J. A.; Mechoulam, R.; Fernandez-Ruiz, J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 2005, 19, 96-107.
246. Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fride, E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U S A, 1999, 96, 14228-33.
247. Wiley, J. L.; Beletskaya, I. D.; Ng, E. W.; Dai, Z.; Crocker, P. J.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J. Pharmacol. Exp. Ther., 2002, 301, 679-89.
248. Huffmann, J. W. D. Dong Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 1994, 4, 563-66.